Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA: 510(k)-Exempt Class II Devices Should Withdraw Applications

Executive Summary

In line with the 21st Century Cures Act, US FDA has finalized a list of class II devices that will no longer need pre-market notification to get to market. Also, check out our updated Cures Act implementation table.

You may also be interested in...



US FDA Exempts 200 Device Types From Premarket Notification

The US FDA has finalized regulations exempting hundreds of class I and class II medical devices from premarket notification requirements.

5 Figures On 510(k) Exemptions: What's The Impact Of US FDA's Recent Actions?

The 21st Century Cures act requires FDA to identify devices to exempt from 510(k) review, a mandate the agency fulfilled earlier this year. But what will be the tangible impact of the hundreds of new device codes removed from 510(k) requirements? This graphical analysis, conducted in collaboration with regulatory intelligence specialist Graematter, shows the effect may not be as large as the top-line numbers suggest. But select specialties and companies may see a few meaningful burdens lifted.

Market Intel: Orthobiologics Market Well-Positioned For Innovative Reconstruction

Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.

Related Content

Topics

UsernamePublicRestriction

Register

MT105130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel